Back to Search Start Over

Over-activation of AKT signaling leading to 5-Fluorouracil resistance in SNU-C5/5-FU cells

Authors :
Jin Won Hyun
Hee Kyoung Kang
Young Sang Koh
Gyeoung Jin Kang
Eun Sook Yoo
Young Hee Maeng
Jung Mi Kwon
Weon Young Chang
Eun Ji Kim
Chang-Hoon Lee
Hye Jin Boo
Young Ree Kim
Jung Il Kang
Source :
Oncotarget
Publication Year :
2018

Abstract

Here, we investigated whether over-activation of AKT pathway is important in the resistance to 5-fluorouracil (5-FU) in SNU-C5/5-FU cells, 5-FU-resistant human colon cancer cells. When compared to wild type SNU-C5 cells (WT), SNU-C5/5-FU cells showed over-activation of PI3K/AKT pathway, like increased phosphorylation of AKT, mTOR, and GSK-3β, nuclear localization of β-catenin, and decreased E-cadherin. Moreover, E-cadherin level was down-regulated in recurrent colon cancer tissues compared to primary colon cancer tissues. Gene silencing of AKT1 or treatment of LY294002 (PI3 kinase inhibitor) increased E-cadherin, whereas decreased phospho-GSK-3β. LY294002 also reduced protein level of β-catenin with no influence on mRNA level. PTEN level was higher in SNU-C5/WT than SNU-C5/5-FU cells, whereas the loss of PETN in SNU-C5/WT cells induced characteristics of SNU-C5/5-FU cells. In SNU-C5/5-FU cells, NF-κB signaling was activated, along with the overexpression of COX-2 and stabilization of survivin. However, increased COX-2 contributed to the stabilization of survivin, which directly interacts with cytoplasmic procaspase-3, while the inhibition of AKT reduced this cascade. We finally confirmed that combination treatment with 5-FU and LY294002 or Vioxx could induce apoptosis in SNU-C5/5-FU cells. These data suggest that inhibition of AKT activation may overcome 5-FU-resistance in SNU-C5/5-FU cells. These findings provide evidence that over-activation of AKT is crucial for the acquisition of resistance to anticancer drugs and AKT pathway could be a therapeutic target for cancer treatment.

Details

ISSN :
19492553
Volume :
9
Issue :
28
Database :
OpenAIRE
Journal :
Oncotarget
Accession number :
edsair.doi.dedup.....f2f4d193cd0683a5cac5349e196e309b